Onco-hematology
Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.
12 Dec, 2022 | 12:37h | UTCGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4
— NEJM (@NEJM) December 11, 2022
Review | AL Amyloidosis for Cardiologists.
6 Dec, 2022 | 13:36h | UTC
Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.
30 Nov, 2022 | 13:39h | UTC
Consensus Paper | Hematopoietic cell transplantation in the management of myelodysplastic syndrome.
29 Nov, 2022 | 14:11h | UTC
Post-trial follow-up | OS with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma.
25 Nov, 2022 | 12:25h | UTCOriginal Study: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
RCT | Zanubrutinib vs. Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
22 Nov, 2022 | 13:03h | UTC
M-A | Prophylactic platelet transfusions vs. no prophylaxis in hospitalized patients with thrombocytopenia.
21 Nov, 2022 | 13:59h | UTC
Single-arm P1/2 study | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma.
11 Nov, 2022 | 13:05h | UTCIberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentaries on Twitter
In a phase I trial of the novel cereblon E3 ligase modulator iberdomide+dexamethasone in pts with RRMM, SAEs occurred in 53%, with one treatment-related death. The ORRs were 32% in the dose-escalation (n=90) & 26% in the dose-expansion (n=107) cohorts: https://t.co/rfRCUfCABb
— NatureRevClinOncol (@NatRevClinOncol) October 14, 2022
NEW research: iberdomide plus dexa was generally safe and showed meaningful clinical activity in heavily pretreated patients with multiple myeloma, including in disease that was refractory to immunomodulatory drugs in this ph 1-2 trial #mmsmhttps://t.co/x1ta31eKtk pic.twitter.com/2URVIoFIAi
— The Lancet Haematology (@TheLancetHaem) October 7, 2022
RCT | Prophylactic tranexamic acid did not decrease bleeding in patients with hematologic malignancy.
10 Nov, 2022 | 13:36h | UTCCommentary: Tranexamic Acid (TXA) Prophylaxis in Patients with Hematologic Malignancies – Physician’s Weekly
RCT | Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin’s Lymphoma.
4 Nov, 2022 | 13:30h | UTCBrentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort Study | Prognostic value of FLT3-internal tandem duplication residual disease in AML.
3 Nov, 2022 | 13:36h | UTC
Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
31 Oct, 2022 | 13:36h | UTC
Commentary on Twitter
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab https://t.co/hw7Tp9yjdu pic.twitter.com/CqMu2cMqRc
— Blood Journal (@BloodJournal) August 31, 2022
Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.
31 Oct, 2022 | 13:34h | UTCCommentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition
Recommendations for laboratory testing of patients with acute myeloid leukemia.
25 Oct, 2022 | 13:21h | UTC
Systematic Review | Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
21 Oct, 2022 | 12:47h | UTC
Guideline | Diagnosis and management of febrile neutropenia in patients with cancer.
18 Oct, 2022 | 12:52h | UTCRelated:
Guidance | Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology.
13 Oct, 2022 | 13:46h | UTC
Cohort Study | Cardiovascular morbidity in monoclonal gammopathy of undetermined significance.
13 Oct, 2022 | 13:34h | UTC
Phase 1 study | GPRC5D-Targeted CAR T Cells for patients with heavily pretreated Multiple Myeloma.
29 Sep, 2022 | 13:25h | UTCGPRC5D-Targeted CAR T Cells for Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.
23 Sep, 2022 | 13:07h | UTC
Commentary on Twitter
Chimeric antigen receptor T cells have revolutionised the treatment of hematological malignancies.
What practical aspects of a patient’s journey through this treatment should clinicians know about and what are current best practices to manage toxicities?https://t.co/idlA2Lv9uR
— The BMJ (@bmj_latest) September 4, 2022
NCCN Guideline | Myeloproliferative neoplasms.
15 Sep, 2022 | 13:05h | UTC
Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.
13 Sep, 2022 | 12:59h | UTCCommentaries:
CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)
CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)
Commentary on Twitter
NEW research—tisagenlecleucel has antitumour activity and acceptable safety in young children and infants (aged younger than 3 years at screening) with B-cell ALL: results of an international, retrospective study #leusm #pedonc #tcellrx https://t.co/kdh3dW5PRU pic.twitter.com/FgQZKQWtXV
— The Lancet Haematology (@TheLancetHaem) September 8, 2022
RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.
11 Sep, 2022 | 22:24h | UTC
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
RCT | Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time.
8 Sep, 2022 | 14:34h | UTCLenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link to abstract – $ for full-text)